Orgel E, Mueske N M, Wren T A L, Gilsanz V, Butturini A M, Freyer D R, Mittelman S D
Children's Center for Cancer and Blood Disease, Children's Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027, USA; Jonathan Jaques Children's Cancer Center, Miller Children's Hospital Long Beach, 2801 Atlantic Avenue, Long Beach, CA 90806, USA; University of Southern California, Los Angeles, CA 90089, USA.
Children's Orthopaedic Center, Children's Hospital Los Angeles, 4650 Sunset Blvd, Los Angeles, CA 90027, USA.
Bone. 2016 Apr;85:131-7. doi: 10.1016/j.bone.2016.01.027. Epub 2016 Feb 3.
Diminished bone density and skeletal fractures are common morbidities during and following therapy for acute lymphoblastic leukemia (ALL). While cumulative doses of osteotoxic chemotherapy for ALL have been reported to adversely impact bone density, the timing of onset of this effect as well as other changes to bone structure is not well characterized. We therefore conducted a prospective cohort study in pre-adolescent and adolescent patients (10-21years) newly diagnosed with ALL (n=38) to explore leukemia-related changes to bone at diagnosis and the subsequent impact of the first phase of chemotherapy ("Induction"). Using quantitative computerized tomography (QCT), we found that pre-chemotherapy bone properties were similar to age- and sex-matched controls. Subsequently over the one month Induction period, however, cancellous volumetric bone mineral density (vBMD) decreased markedly (-26.8%, p<0.001) with sparing of cortical vBMD (tibia -0.0%, p=0.860, femur -0.7%, p=0.290). The tibia underwent significant cortical thinning (average cortical thickness-1.2%, p<0.001; cortical area-0.4%, p=0.014), while the femur was less affected. Areal BMD (aBMD) concurrently measured by dual-energy X-ray absorptiometry (DXA) underestimated changes from baseline as compared to vBMD. Biochemical evidence revealed prevalent Vitamin D insufficiency and a net resorptive state at start and end of Induction. Our findings demonstrate for the first time that significant alterations to cancellous and cortical bone develop during the first month of treatment, far earlier during ALL therapy than previously considered. Given that osteotoxic chemotherapy is integral to curative regimens for ALL, these results provide reason to re-evaluate traditional approaches toward chemotherapy-associated bone toxicity and highlight the urgent need for investigation into interventions to mitigate this common adverse effect.
骨密度降低和骨骼骨折是急性淋巴细胞白血病(ALL)治疗期间及治疗后的常见病症。虽然据报道,ALL的骨毒性化疗累积剂量会对骨密度产生不利影响,但这种影响的起始时间以及骨骼结构的其他变化尚未得到充分表征。因此,我们对新诊断为ALL的青春期前和青少年患者(10 - 21岁,n = 38)进行了一项前瞻性队列研究,以探讨诊断时白血病相关的骨骼变化以及化疗第一阶段(“诱导期”)的后续影响。使用定量计算机断层扫描(QCT),我们发现化疗前的骨骼特性与年龄和性别匹配的对照组相似。然而,在随后的一个月诱导期内,松质骨体积骨密度(vBMD)显著下降(-26.8%,p < 0.001),而皮质骨vBMD保持不变(胫骨 -0.0%,p = 0.860,股骨 -0.7%,p = 0.290)。胫骨出现明显的皮质变薄(平均皮质厚度 -1.2%,p < 0.001;皮质面积 -0.4%,p = 0.014),而股骨受影响较小。与vBMD相比,通过双能X线吸收法(DXA)同时测量的面积骨密度(aBMD)低估了与基线的变化。生化证据显示,诱导期开始和结束时普遍存在维生素D不足和净吸收状态。我们的研究结果首次表明,在治疗的第一个月内,松质骨和皮质骨发生了显著变化,这比之前认为的在ALL治疗期间要早得多。鉴于骨毒性化疗是ALL治愈方案的组成部分,这些结果为重新评估传统的化疗相关骨毒性方法提供了理由,并突出了迫切需要研究减轻这种常见不良反应的干预措施。